Gastrointestinal Stromal Tumor Clinical Pipeline | 25+ Companies Advancing the Future of Treatment

The Gastrointestinal Stromal Tumor market is rapidly evolving with cutting-edge research and breakthrough therapies driven by leading companies like Ascentage Pharma, Takeda, Array BioPharma, and Plexxikon. These innovators are revolutionizing treatment approaches and shaping the future of Gastrointestinal Stromal Tumor care, offering new hope for patients worldwide.

DelveInsight's 'Gastrointestinal Stromal Tumor Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Gastrointestinal Stromal Tumor therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Gastrointestinal Stromal Tumor pipeline domain.

For emerging Gastrointestinal Stromal Tumor drugs, the Gastrointestinal Stromal Tumor pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Gastrointestinal Stromal Tumor Pipeline Report
• DelveInsight's Gastrointestinal Stromal Tumor Pipeline analysis depicts a robust space with 25+ active players working to develop 28+ pipeline drugs for Gastrointestinal Stromal Tumor treatment.
• The leading Gastrointestinal Stromal Tumor companies include Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, and others are evaluating their lead assets to improve the Gastrointestinal Stromal Tumor treatment landscape.
• Key Gastrointestinal Stromal Tumor pipeline therapies in various stages of development include Crenolanib, TAS-116, Bezuclastinib, Famitinib, Nilotinib, THE-630, DS 6157, and others.
• In December 2024, the FDA granted EndoQuest Robotics, Inc. an Investigational Device Exemption (IDE) for its pivotal colorectal clinical study, Prospective Assessment of a Robotic-Assisted Device in Gastrointestinal Medicine (PARADIGM). EndoQuest is a pioneer in developing flexible endoluminal robotic technologies.

Request a sample and discover the recent breakthroughs happening in the Gastrointestinal Stromal Tumor pipeline landscape @ https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Gastrointestinal Stromal Tumor Overview
Gastrointestinal Stromal Tumors (GISTs) are a type of cancer classified under sarcomas-malignant tumors that originate in various tissues, including fat, muscle, nerves, cartilage, bone, blood vessels, and lymphatic vessels. This sets sarcomas apart from other cancers, such as carcinomas, which develop from the linings of organs and tissues (e.g., lung, colon, breast, prostate, and pancreas), lymphomas, which arise from immune cells in lymph nodes, and leukemias, which originate from immune cells in the bone marrow.

GISTs can cause a range of symptoms, both subjective and objective. Patients may experience nausea, early satiety, bloating, and weight loss, while objective signs may include anemia (low red blood cell count) or a noticeable lump in the abdomen. The presentation of these symptoms varies based on the tumor's location (e.g., stomach vs. rectum), size, and growth pattern.

Find out more about Gastrointestinal Stromal Tumor medication @ https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Gastrointestinal Stromal Tumor Treatment Analysis: Drug Profile
Famitinib: Jiangsu Hengrui Medicine
Famitinib is an orally active small-molecule tyrosine kinase inhibitor that targets multiple receptors, including vascular endothelial growth factor receptor (VEGFR) 2/3, platelet-derived growth factor receptor (PDGFR), and stem cell factor receptor (c-kit). Jiangsu Hengrui Medicine Co. is developing famitinib for a range of advanced-stage solid tumors. Currently, the drug is in Phase III clinical trials for the treatment of Gastrointestinal Stromal Tumors (GIST).

Nilotinib: Novartis
Tasigna (nilotinib hydrochloride monohydrate) is an orally administered signal transduction inhibitor that targets Bcr-Abl kinase, c-kit, and platelet-derived growth factor (PDGF), all of which contribute to cell proliferation, migration, and angiogenesis. It is specifically approved for the treatment of chronic-phase and accelerated-phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in adult patients who are resistant or intolerant to prior therapy, including imatinib. Nilotinib is currently being evaluated in a Phase II clinical trial to assess its potential in treating gastrointestinal stromal tumors.

Key Gastrointestinal Stromal Tumor Therapies and Companies
• Crenolanib: Arog Pharmaceuticals
• TAS-116: Taiho Pharmaceutical
• Bezuclastinib (CGT9486/PLX9486): Cogent Biosciences, Inc. / Plexxikon Inc.
• Famitinib: Jiangsu Hengrui Medicine
• Nilotinib: Novartis
• THE-630: Theseus Pharmaceuticals
• DS 6157: Daiichi Sankyo Company

Learn more about the novel and emerging Gastrointestinal Stromal Tumor pipeline therapies @ https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Gastrointestinal Stromal Tumor Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Gastrointestinal Stromal Tumor Pipeline Report
• Coverage: Global
• Key Gastrointestinal Stromal Tumor Companies: Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, and others.
• Key Gastrointestinal Stromal Tumor Pipeline Therapies: Crenolanib, TAS-116, Bezuclastinib, Famitinib, Nilotinib, THE-630, DS 6157, and others.

Dive deep into rich insights for drugs used for Gastrointestinal Stromal Tumor treatment; visit @ https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Gastrointestinal Stromal Tumor Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Gastrointestinal Stromal Tumor Pipeline Therapeutics
6. Gastrointestinal Stromal Tumor Pipeline: Late-Stage Products (Phase III)
7. Gastrointestinal Stromal Tumor Pipeline: Late-Stage Products (Phase III)
8. Gastrointestinal Stromal Tumor Pipeline: Mid-Stage Products (Phase II)
9. Gastrointestinal Stromal Tumor Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.